A reported recurrence of stress cardiomyopathy after changes in lorazepam use illustrates why the medication timeline matters alongside cardiac findings.
The patient was a 40-year-old woman with previous episodes of Takotsubo and reverse Takotsubo cardiomyopathy. Her maintenance lorazepam had been changed to an as-needed regimen about a month before the new presentation. She described taking larger amounts on some days followed by reductions. The authors attributed her recurrent cardiomyopathy to benzodiazepine withdrawal.
The acute illness was severe: cardiogenic shock, an ejection fraction of approximately 10–15%, and apical hypokinesis. Treatment included venoarterial extracorporeal membrane oxygenation and an intra-aortic balloon pump. Ventricular function subsequently recovered to about 60%.
This is a single clinical report, not a measurement of how frequently lorazepam withdrawal causes cardiomyopathy. Alcohol use, stimulant exposure, recent respiratory illness, and other potential explanations formed part of the clinical assessment. Recovery after intensive treatment does not isolate the effect of any one intervention.
For a record review, distinguish the prescription instruction, actual daily consumption, gaps or reductions, symptom onset, and cardiac investigations. A label such as “as needed” does not reconstruct exposure by itself. The paper supports considering withdrawal in the differential diagnosis of stress cardiomyopathy; it does not establish that every cardiac event after a prescription change has that cause.
Original analysis of the supplied journal article, identified as PMC12926048.